Rybelsus 3mg is the initiation-strength dose of Semaglutide, an oral glucagon-like peptide-1 (GLP-1) receptor agonist. This medication provides physiological support for glycemic management in adults with type 2 diabetes by augmenting glucose-dependent insulin secretion and reducing glucagon release, facilitating the transition to higher therapeutic maintenance doses.

Dosage & Administration

• 1 tablet per day.
• Duration: Administer the 3mg dose for exactly 30 days to initiate treatment and improve gastrointestinal tolerability before escalating to the 7mg maintenance dose.
• Administer orally on an empty stomach immediately upon waking.
• Liquid limit: Take with exactly 120ml (4 ounces) or less of plain water.
• Wait period: Do not consume food, beverages, or other oral medications for at least 30 minutes following administration.
• Swallow whole: Do not crush, chew, or split the tablet, as this compromises the SNAC-mediated absorption mechanism.

Safety & Storage

• Adverse Reactions: Nausea, vomiting, and diarrhea are common during the initiation phase but typically diminish with continued use.
• Storage: Store in the original blister pack until administration to prevent moisture degradation. Keep at a temperature below 30°C.